Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 389.13M | 373.16M | 359.21M | 333.45M | 290.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 389.13M | 373.16M | 359.21M | 333.45M | 290.51M |
| Cost of Revenue | 23.05M | 21.41M | 23.83M | 22.67M | 20.06M |
| Gross Profit | 366.08M | 351.76M | 335.38M | 310.78M | 270.45M |
| SG&A Expenses | 146.91M | 136.75M | 127.84M | 120.31M | 113.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.00M | 214.93M | 207.37M | 199.86M | 187.29M |
| Operating Income | 161.13M | 158.23M | 151.83M | 133.59M | 103.23M |
| Income Before Tax | 189.47M | 186.95M | 168.75M | 138.02M | 95.36M |
| Income Tax Expenses | -15.36M | -11.96M | 22.03M | 14.06M | 6.20M |
| Earnings from Continuing Operations | 204.83 | 198.91 | 146.73 | 123.96 | 89.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 204.83M | 198.91M | 146.73M | 123.96M | 89.16M |
| EBIT | 161.13M | 158.23M | 151.83M | 133.59M | 103.23M |
| EBITDA | 162.75M | 159.56M | 153.20M | 135.94M | 105.70M |
| EPS Basic | 7.07 | 6.89 | 5.09 | 4.31 | 3.11 |
| Normalized Basic EPS | 4.09 | 4.05 | 3.93 | 3.55 | 2.90 |
| EPS Diluted | 6.85 | 6.68 | 4.93 | 4.17 | 3.00 |
| Normalized Diluted EPS | 3.96 | 3.92 | 3.80 | 3.41 | 2.79 |
| Average Basic Shares Outstanding | 115.77M | 115.43M | 115.20M | 114.88M | 114.36M |
| Average Diluted Shares Outstanding | 119.70M | 119.34M | 119.41M | 119.29M | 118.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |